Breyanzi
Sep 02, 2024
CAR T-Cell Therapies in Non-Hodgkin’s Lymphoma Treatment: A Revolutionary Approach
CAR-T cells offer a lasting benefit through a single treatment, sparing patients with high-risk conditions from the toxicity associated with salvage chemotherapy and autologous transplants. These approvals have changed the standard of care for patients who are either resistant to initial treatment or experience ear...
Read More...
Feb 09, 2021
Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia
Deerfield and Dana-Farber Establish Links in USD 130 Million Cancer Research Deal Deerfield Management has entered into a research agreement with Dana-Farber Cancer Institute to fuel the development of therapeutics and diagnostics for cancer. The move came not long after healthcare investor giant Deerfield...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
